Navigation Links
Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
Date:6/27/2011

proximately 50 sites in the United States.  For additional information on this study, please see www.clinicaltrials.gov (ID NCT01376557).

About LX4211

LX4211 is an orally-delivered small molecule under development as a potential treatment for diabetes.  LX4211 inhibits both sodium-glucose co-transporter type 1 (SGLT1) and sodium-glucose co-transporter type 2 (SGLT2).  SGLT2 is a transporter responsible for most of the glucose reabsorption performed by the kidney.  SGLT1 is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney.  For more information on LX4211, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of clinical trials of LX4211, the mechanism of action of LX4211 and the potential therapeutic and commercial potential of LX4211.  This press release also contains for
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Although lung ... the world, there are only 18 drugs in the ... Almita and Avastin are nearing their patent expiry in ... therapeutics market offers vast potential that drug manufacturers are ... treatment of small cell lung cancer (SCLC) and non-small ...
(Date:3/3/2015)... , March 3, 2015 ImmunoCellular Therapeutics, ... Andrew Gengos , Chief Executive Officer of ImmunoCellular, will ... 27 th Annual ROTH Conference on Tuesday, March ... Hotel, Laguna Niguel , CA.   ... the ROTH presentation, please log on through a link ...
(Date:3/3/2015)... , March 3, 2015 Chrono Therapeutics ... an investment by Rock Health , the leading ... of Chrono,s SmartStop™ programmable transdermal drug delivery system and ... Smoking kills more than 500,000 Americans each year, ... in the United States . Of ...
Breaking Medicine Technology:Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 2Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 3ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 3
... N.J., Sept. 28 Laureate Pharma, Inc., ... company, today announced the appointment of Steven ... Mr. Johnson will be responsible for Laureate,s ... business development and project management, supporting the ...
... JUNCTION, N.J., Sept. 28 Tamir Biotechnology, Inc. ... Corporation) announced today that scientists supported by the ... reported test results confirming two of our lead ... cell culture and plaque reduction assay (the gold ...
Cached Medicine Technology:Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development 2New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4
(Date:3/3/2015)... (PRWEB) March 03, 2015 United Benefit ... organization, is pleased to welcome The Gehring Group, Inc. ... consulting services for more than 20 years, The Gehring ... benefits and risk management consulting firm that serves organizations ... and risk management programs. , Based in ...
(Date:3/3/2015)... Grants Pass, OR (PRWEB) March 03, 2015 ... and stroke severity* confirms what water advocate and radio ... believes that dehydration – lack of sufficient water in ... affect as much as 90 percent of the US ... that dehydration is a factor in nearly all disease, ...
(Date:3/3/2015)... Everett, WA (PRWEB) March 03, 2015 ... dedication to a lifestyle of fitness and exercise. Community ... an article presenting 6 ways that families in ... fit during the winter months. , CHC says, ... for grilled chicken and steamed veggies, many families wonder ...
(Date:3/3/2015)... 2015 Prophecy Healthcare®, Inc., the ... care testing, is now conducting dedicated research to ... result of acquiring the exam rights and Intellectual ... 2014, the research will soon create more health ... providers, healthcare staffing organizations and more. ...
(Date:3/3/2015)... 03, 2015 Extend Nutrition, a leading nutritional ... amount of calories consumed at the next meal by an ... There are no lifestyle changes needed and no program to ... day. , The starter kit contains 60 servings of nutritional ... of protein, fiber, healthy fat and complex carbohydrates that helps ...
Breaking Medicine News(10 mins):Health News:United Benefit Advisors Welcomes New Partner Firm The Gehring Group, Inc. 2Health News:United Benefit Advisors Welcomes New Partner Firm The Gehring Group, Inc. 3Health News:Study linking dehydration and stroke severity supports fresh water advocate’s warnings 2Health News:Study linking dehydration and stroke severity supports fresh water advocate’s warnings 3Health News:6 Wintertime Weight Loss Tips for Family Fitness Presented by Community Health Center of Snohomish County in Recent Article 2Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 2Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 3Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 2Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 3
... Drug Administration (FDA) have approved a virus mix in spray ... given last month.// , ,Processed meats after being ... is a combination of viruses that kill this bacteria. Food ... and distribution. ,This virus mix is not effective ...
... crisp habit is prevalent among 55% of the British children and ... ,The BHF started a campaign to create awareness among ... common foods and the figures were releases as a part of ... oil, salt and sugar as we and our children continue to ...
... actors, echoed The Bard, eons ago. As the curtains go ... today on// World Alzheimer’s day, the stage is set for deep ... and evolve better strategies for effective management of the disease. ... nervous system marked by stark and untimely backslide in the patient’s ...
... biological markers that can predict disability, morbidity and ... researchers// analyzed 13 biomarkers representing neuroendocrine and vascular ... years in 1,189 high-functioning men and women aged ... Aging. The goals were to identify biomarker combinations ...
... over plans of British hospitals to outsource medical transcription to ... are not shelved.// ,Several hospitals in Britain have outsourced ... typing up patients' notes to India to save costs at ... hospitals in Staffordshire, Leeds and Cornwall. ,At the ...
... reported having updated the warning label on the Ortho ... of blood clots from it.// ,The drug manufacturer ... faced two times the risk of clots in the ... pills. ,Another study commissioned by Johnson and Johnson, ...
Cached Medicine News:Health News:World Alzheimer’s Day: In Memory of Those With 'Memory Loss 2Health News:World Alzheimer’s Day: In Memory of Those With 'Memory Loss 3Health News:Britain Hospital Staff Threatens Strike 2Health News:Contraceptive Patch Carries Risk of Blood clots 2
... automated patient ID verification and laboratory specimen labeling ... of the phlebotomist or nurse, the identity of ... proper verification is made, a bar coded sample ... Its unique design simplifies and eliminates the interface ...
... Bridge™ Specimen Collections, a Cerner ... for specimen identification and collection. The ... of the specimen collections process by ... and clinical information system integration to ...
... bar-code medication administration solution that safely automates ... bar-code technology. Caregivers use a wireless bar-code ... to verify that the right patient receives ... in the right dosage via the right ...
... Korchek Technologies CareChek ... employs barcode technology, Windows ... with integrated scanners (to ... at the bedside) and ...
Medicine Products: